NCT04543344View on ClinicalTrials.gov

Study To Evaluate The Pharmacokinetic, Safety And Tolerability Of Single Or Multiple Subcutaneous Doses of Recifercept

PHASE1CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

September 17, 2020

Primary Completion Date

August 3, 2021

Study Completion Date

November 26, 2021

Conditions
Healthy
Interventions
DRUG

Recifercept

recifercept powder for solution for injection

OTHER

Placebo

solution for injection

Trial Locations (1)

B-1070

Brussels Clinical Research Unit, Brussels

Sponsors

Lead Sponsor

Pfizer
All Listed Sponsors
lead

Pfizer

INDUSTRY

NCT04543344 - Study To Evaluate The Pharmacokinetic, Safety And Tolerability Of Single Or Multiple Subcutaneous Doses of Recifercept | Biotech Hunter | Biotech Hunter